Preference phenotypes to facilitate shared decision-making in rheumatoid arthritis. Issue 5 (15th December 2017)

• Record Type: Journal Article
• Authors: Fraenkel, Liana; Nowell, W Benjamin; Michel, George; Wiedmeyer, Carole
• Is Part Of: Annals of the rheumatic diseases. Volume 77:Issue 5(2018)
• Page Start: 678
• Page End: 683
• Publication Date: 2017-12-15
• Subjects: rheumatoid arthritis -- dmards (biologic) -- dmards (synthetic) -- patient perspective; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2017-212407
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objective: Implementing treat-to-target (TTT) strategies requires that patients with rheumatoid arthritis (RA) and their rheumatologists decide on how best to escalate care when indicated. The objective of this study was to develop preference phenotypes to facilitate shared decision-making at the point of care for patients failing methotrexate monotherapy. Methods: We developed a conjoint analysis survey to measure the preferences of patient with RA for triple therapy, biologics and Janus kinase (JAK) inhibitors. The survey included seven attributes: administration, onset, bothersome side effects, serious infection, very rare side effects, amount of information and cost. Each choice set (n=12) included three hypothetical profiles. Preference phenotypes were identified by applying latent class analysis to the conjoint data. Results: 1273 participants completed the survey. A five-group solution was chosen based on progressively lower values of the Akaike and Bayesian information criteria. Members of the largest group (group 3: 38.4%) were most strongly impacted by the cost of the medication. The next largest group (group 1: 25.8%) was most strongly influenced by the risk of bothersome side effects. Members of group 2 (11.2%) were also risk averse, but were most concerned with the risk of very rare side effects. Group 4 (6.6%) strongly preferred oral over parenteral medications. Members of group 5 (18.0%) were most strongly and equally influenced by onset of action and the risk of serious infections. Conclusions: Treatment preferences of patients with RA can be measured and represented by distinct phenotypes. Our results underscore the variability in patients' values and the importance of using a shared decision-making approach to implement TTT.